Mitochondrial dysfunction and tau aggregation occur in Alzheimer’s disease (AD), and exposing cells or rodents to mitochondrial toxins alters their tau.
Objective:
To further explore how mitochondria influence tau, we measured tau oligomer levels in human neuronal SH-SY5Y cells with different mitochondrial DNA (mtDNA) manipulations.
Methods:
Specifically, we analyzed cells undergoing ethidium bromide-induced acute mtDNA depletion, ρ0 cells with chronic mtDNA depletion, and cytoplasmic hybrid (cybrid) cell lines containing mtDNA from AD subjects.
Results:
We found cytochrome oxidase activity was particularly sensitive to acute mtDNA depletion, evidence of metabolic re-programming in the ρ0 cells, and a relatively reduced mtDNA content in cybrids generated through AD subject mitochondrial transfer. In each case tau oligomer levels increased, and acutely depleted and AD cybrid cells also showed a monomer to oligomer shift.
Conclusion:
We conclude a cell’s mtDNA affects tau oligomerization. Overlapping tau changes across three mtDNA-manipulated models establishes the reproducibility of the phenomenon, and its presence in AD cybrids supports its AD-relevance.
SwerdlowRH (2007) Is aging part of Alzheimer’s disease, or is Alzheimer’s disease part of aging?Neurobiol Aging28, 1465–1480.
2.
SwerdlowRH (2012) Mitochondria and cell bioenergetics: Increasingly recognized components and a possible etiologic cause of Alzheimer’s disease. Antioxid Redox Signal16, 1434–1455.
3.
ManczakM, ReddyPH (2012) Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: Implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet21, 2538–2547.
4.
QuintanillaRA, Matthews-RobersonTA, DolanPJ, JohnsonGV (2009) Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: Implications for the pathogenesis of Alzheimer disease. J Biol Chem284, 18754–18766.
5.
AtlanteA, AmadoroG, BobbaA, de BariL, CorsettiV, PappalardoG, MarraE, CalissanoP, PassarellaS (2008) A peptide containing residues 26-44 of tau protein impairs mitochondrial oxidative phosphorylation acting at the level of the adenine nucleotide translocator. Biochim Biophys Acta1777, 1289–1300.
6.
CieriD, VicarioM, ValleseF, D’OrsiB, BertoP, GrinzatoA, CatoniC, De StefaniD, RizzutoR, BriniM, CaliT (2018) Tau localises within mitochondrial sub-compartments and its caspase cleavage affects ER-mitochondria interactions and cellular Ca(2+) handling. Biochim Biophys Acta Mol Basis Dis1864, 3247–3256.
7.
BlassJP, BakerAC, KoL, BlackRS (1990) Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch Neurol47, 864–869.
8.
BruchJ, XuH, De AndradeA, HoglingerG (2014) Mitochondrial complex 1 inhibition increases 4-repeat isoform tau by SRSF2 upregulation. PLoS One9, e113070.
9.
HoglingerGU, LannuzelA, KhondikerME, MichelPP, DuyckaertsC, FegerJ, ChampyP, PrigentA, MedjaF, LombesA, OertelWH, RubergM, HirschEC (2005) The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem95, 930–939.
10.
RottschollR, HaegeleM, JainschB, XuH, RespondekG, HollerhageM, RoslerTW, BonyE, Le VenJ, GuerineauV, Schmitz-AfonsoI, ChampyP, OertelWH, YamadaES, HoglingerGU (2016) Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau phosphorylation in wild-type and MAPT transgenic mice. J Neurochem139, 624–639.
11.
HollerhageM, DeckR, De AndradeA, RespondekG, XuH, RoslerTW, SalamaM, CarlssonT, YamadaES, Gad El HakSA, GoedertM, OertelWH, HoglingerGU (2014) Piericidin A aggravates Tau pathology in P301S transgenic mice. PLoS One9, e113557.
12.
YamadaES, RespondekG, MussnerS, de AndradeA, HollerhageM, DepienneC, RastetterA, TarzeA, FriguetB, SalamaM, ChampyP, OertelWH, HoglingerGU (2014) Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice. Exp Neurol253, 113–125.
13.
Escobar-KhondikerM, HollerhageM, MurielMP, ChampyP, BachA, DepienneC, RespondekG, YamadaES, LannuzelA, YagiT, HirschEC, OertelWH, JacobR, MichelPP, RubergM, HoglingerGU (2007) Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci27, 7827–7837.
ZhongJ, IqbalK, Grundke-IqbalI (1999) Hyperphosphorylated tau in SY5Y cells: Similarities and dissimilarities to abnormally hyperphosphorylated tau from Alzheimer disease brain. FEBS Lett453, 224–228.
16.
ShafieiSS, Guerrero-MunozMJ, Castillo-CarranzaDL (2017) Tau oligomers: Cytotoxicity, propagation, and mitochondrial damage. Front Aging Neurosci9, 83.
17.
MillerSW, TrimmerPA, ParkerWDJr, DavisRE (1996) Creation and characterization of mitochondrial DNA-depleted cell lines with “neuronal-like” properties. J Neurochem67, 1897–1907.
18.
SwerdlowRH, ParksJK, MillerSW, TuttleJB, TrimmerPA, SheehanJP, BennettJPJr, DavisRE, ParkerWDJr (1996) Origin and functional consequences of the complex I defect in Parkinson’s disease. Ann Neurol40, 663–671.
19.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
20.
SwerdlowRH, EL, AiresD, LuJ (2013) Glycolysis-respiration relationships in a neuroblastoma cell line. Biochim Biophys Acta1830, 2891–2898.
21.
WardSM, HimmelsteinDS, LanciaJK, FuY, PattersonKR, BinderLI (2013) TOC1: Characterization of a selective oligomeric tau antibody. J Alzheimers Dis37, 593–602.
22.
PattersonKR, RemmersC, FuY, BrookerS, KanaanNM, VanaL, WardS, ReyesJF, PhilibertK, GlucksmanMJ, BinderLI (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem286, 23063–23076.
23.
GhoshalN, Garcia-SierraF, WuuJ, LeurgansS, BennettDA, BerryRW, BinderLI (2002) Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer’s disease. Exp Neurol177, 475–493.
24.
GuoW, JiangL, BhasinS, KhanSM, SwerdlowRH (2009) DNA extraction procedures meaningfully influence qPCR-based mtDNA copy number determination. Mitochondrion9, 261–265.
25.
RygielKA, GradyJP, TaylorRW, TuppenHA, TurnbullDM (2015) Triplex real-time PCR–an improved method to detect a wide spectrum of mitochondrial DNA deletions in single cells. Sci Rep5, 9906.
26.
RioDC, AresMJr., HannonGJ, NilsenTW (2010) Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc2010, pdb.prot5439.
27.
JanssenAJ, TrijbelsFJ, SengersRC, SmeitinkJA, van den HeuvelLP, WintjesLT, Stoltenborg-HogenkampBJ, RodenburgRJ (2007) Spectrophotometric assay for complex I of the respiratory chain in tissue samples and cultured fibroblasts. Clin Chem53, 729–734.
28.
FotakisG, TimbrellJA (2006) In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett160, 171–177.
29.
HashiguchiK, Zhang-AkiyamaQM (2009) Establishment of human cell lines lacking mitochondrial DNA. Methods Mol Biol554, 383–391.
30.
ReddyP, OcampoA, SuzukiK, LuoJ, BacmanSR, WilliamsSL, SugawaraA, OkamuraD, TsunekawaY, WuJ, LamD, XiongX, MontserratN, EstebanCR, LiuGH, Sancho-MartinezI, ManauD, CivicoS, CardellachF, Del Mar O’CallaghanM, CampistolJ, ZhaoH, CampistolJM, MoraesCT, Izpisua BelmonteJC (2015) Selective elimination of mitochondrial mutations in the germline by genome editing. Cell161, 459–469.
31.
NagyZ, EsiriMM, LeGrisM, MatthewsPM (1999) Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathol97, 346–354.
32.
FioreseCJ, SchulzAM, LinYF, RosinN, PellegrinoMW, HaynesCM (2016) The transcription factor ATF5 mediates a mammalian mitochondrial UPR. Curr Biol26, 2037–2043.
33.
WeidlingI, SwerdlowRH (2019) Mitochondrial dysfunction and stress responses in Alzheimer’s disease. Biology (Basel)8, 39.
34.
RocherC, TaanmanJW, PierronD, FaustinB, BenardG, RossignolR, MalgatM, PedespanL, LetellierT (2008) Influence of mitochondrial DNA level on cellular energy metabolism: Implications for mitochondrial diseases. J Bioenerg Biomembr40, 59–67.
35.
Fernandez-VizarraE, EnriquezJA, Perez-MartosA, MontoyaJ, Fernandez-SilvaP (2011) Tissue-specific differences in mitochondrial activity and biogenesis. Mitochondrion11, 207–213.
36.
SwerdlowRH, ParksJK, CassarinoDS, MaguireDJ, MaguireRS, BennettJPJr, DavisRE, ParkerWDJr (1997) Cybrids in Alzheimer’s disease: A cellular model of the disease?Neurology49, 918–925.
37.
RiceAC, KeeneyPM, AlgarzaeNK, LaddAC, ThomasRR, BennettJPJr. (2014) Mitochondrial DNA copy numbers in pyramidal neurons are decreased and mitochondrial biogenesis transcriptome signaling is disrupted in Alzheimer’s disease hippocampi. J Alzheimers Dis40, 319–330.
38.
WeiW, KeoghMJ, WilsonI, CoxheadJ, RyanS, RollinsonS, GriffinH, Kurzawa-AkanbiM, Santibanez-KorefM, TalbotK, TurnerMR, McKenzieC-A, TroakesC, AttemsJ, SmithC, Al SarrajS, MorrisCM, AnsorgeO, Pickering-BrownS, IronsideJW, ChinneryPF (2017) Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta Neuropathol Commun5, 13.
39.
ZhangR, WangY, YeK, PicardM, GuZ (2017) Independent impacts of aging on mitochondrial DNA quantity and quality in humans. BMC Genomics18, 890–890.
40.
BrownAM, SheuRK, MohsR, HaroutunianV, BlassJP (2001) Correlation of the clinical severity of Alzheimer’s disease with an aberration in mitochondrial DNA (mtDNA). J Mol Neurosci16, 41–48.
41.
DavisRE, MillerS, HerrnstadtC, GhoshSS, FahyE, ShinobuLA, GalaskoD, ThalLJ, BealMF, HowellN, ParkerWDJr (1997) Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci U S A94, 4526–4531.
de la MonteSM, LuongT, NeelyTR, RobinsonD, WandsJR (2000) Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer’s disease. Lab Invest80, 1323–1335.
44.
AttardiG, SchatzG (1988) Biogenesis of Mitochondria. Ann Rev Cell Biol4, 289–331.
45.
FalkenbergM (2018) Mitochondrial DNA replication in mammalian cells: Overview of the pathway. Essays Biochem62, 287–296.
46.
StonekingM (2000) Hypervariable sites in the mtDNA control region are mutational hotspots. Am J Hum Genet67, 1029–1032.
47.
LeeH-C, LiS-H, LinJ-C, WuC-C, YehD-C, WeiY-H (2004) Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res547, 71–78.
48.
MacaulayV, RichardsM, HickeyE, VegaE, CrucianiF, GuidaV, ScozzariR, Bonné-TamirB, SykesB, TorroniA (1999) The emerging tree of West Eurasian mtDNAs: A synthesis of control-region sequences and RFLPs. Am J Hum Genet64, 232–249.
49.
MichikawaY, MazzucchelliF, BresolinN, ScarlatoG, AttardiG (1999) Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science286, 774.
50.
CoskunPE, BealMF, WallaceDC (2004) Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A101, 10726–10731.
51.
RidgePG, KauweJSK (2018) Mitochondria and Alzheimer’s disease: The role of mitochondrial genetic variation. Curr Genet Med Rep6, 1–10.
